Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/238709
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Maintenance of virologic suppression and improvement in comorbidities after simplification to raltegravir plus boosted darunavir among treatment-experienced HIV-infected patients |
Autor: | Casado Chocán, José Luis; Vizcarra, Pilar; Blanco, José L.; Montejano, Rocío; Negredo, Eugenia; Espinosa, Nuria CSIC ORCID; Montero, Marta; Mena, Álvaro; Palacios, Rosario; López, Juan Carlos; Vergas, Jorge; Galindo, María José; Cabello, Alfonso; García-Deltoro, Miguel; Díaz De Santiago, Alberto | Palabras clave: | Dual therapy Raltegravir Darunavir Switching Simplification Resistance Toxicity |
Fecha de publicación: | 5-mar-2020 | Editor: | Sage Publications | Citación: | International Journal of STD and AIDS (2020) | Resumen: | The use of two potent, well-tolerated, drugs could permit the maintenance of virologic suppression even in heavily pretreated people living with HIV. In this retrospective, multicenter, simplification study (NCT03348449), we included those patients with virologic suppression who switched to raltegravir (RAL) plus boosted darunavir (b/DRV). Overall, 345 patients (75 females, 25%) were included. Patients were largely pretreated (mean, 9.4 regimens), suppressed for a median of 41.1 months. Fifty patients had ≥1 mutation against DRV. At 96 weeks, the efficacy by intention-to-treat analysis (snapshot) was 73% (95%CI, 68.4–77.8%), but 97.1% (95%CI, 95.4–98.9) excluding changes due to non-virologic reasons, and virologic failure was rare (0.9%; 95%CI, 0.1–1.2%). Median CD4/CD8 ratio increased from 0.59 to 0.62 (p < 0.01), CD4+ cell count by +90 cells/µl (p < 0.01), and mean estimated glomerular filtration rate (eGFR) increased from 85.2 to 88.5 ml/min at 96 weeks, greater for patients receiving tenofovir disoproxil fumarate (eGFR, +3.6 ml/min, p = 0.04; serum phosphate +0.33 mg/dl; p < 0.01). There was a continued and significant improvement in the total cholesterol/high-density lipoprotein-cholesterol ratio. In conclusion, the simplification to a dual regimen with the combination of RAL and b/DRV is associated with maintenance of virologic suppression, even in largely pretreated patients, with improvements in CD4+ cell count, CD4/CD8 ratio, and in renal and lipid parameters. | Descripción: | BIRDi study group. | Versión del editor: | http://doi.org/10.1177/0956462419896478 | URI: | http://hdl.handle.net/10261/238709 | DOI: | 10.1177/0956462419896478 | Identificadores: | doi: 10.1177/0956462419896478 issn: 0956-4624 e-issn: 1758-1052 |
Aparece en las colecciones: | (IBIS) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
Page view(s)
59
checked on 22-abr-2024
Download(s)
11
checked on 22-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.